Navigation Links
Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
Date:9/1/2009

FARMINGDALE, N.Y., Sept. 1 /PRNewswire-FirstCall/ -- Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008. In addition to its already established, commission based, contract sales organization, the Company has added 5 experienced, highly trained Region Managers. The Region Managers will support the efforts of the contract sales representatives and will sell Misonix labeled product directly to hospitals and clinics in key markets; including, California, Texas, New York, Florida, and Illinois. In addition to the SonicOne(TM) Wound Management System, which the domestic sales team began to sell in the latter part of calendar 2008, direct to hospital sales of the SonaStar(R) Ultrasonic Surgical Aspirator have now begun. Aesculap, Inc., a division of B. Braun, the German conglomerate, who has sold SonaStar exclusively in the United States in the past, continues to market SonaStar on a non-exclusive basis.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"We are confident that by expanding our domestic sales organization we can grow our revenue in the United States," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "This sales group is designed to increase market penetration and increase revenue for these important products while building customer awareness and brand equity for Misonix. Additionally, we believe this sales team, which is very experienced in the sale of medical equipment and disposables, will provide us with the capability to effectively sell other Misonix labeled products to US clinical customers in the years to come."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million
2. Misonix Receives First Award for Forensic Equipment in China
3. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
4. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
5. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
6. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
7. Misonix Announces Participation in Annual Diabetic Foot Global Conference
8. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
9. Misonix Announces New HIFU Distribution Agreement For Portugal
10. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
11. Misonix Announces New Distribution Agreement for Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 ... ... Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American ... The organization, which plans to publish the first ANSI-approved GMP standard for ...
(Date:3/29/2017)... , ... March 29, 2017 , ... HealthCareMandA.com will host ... April 20, 2017, at 1:00 PM ET. A recording of the webinar will also ... Webinar Series. , Home health and hospice companies are still popular targets for healthcare ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education ... specialized continuing medical education conference for clinicians who manage some of the most ... York. , The program will be led by co- chairs Dr. John ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the ... take the Diabetes Risk Test to find out if they are at risk for ... will light up the evening sky by programming the LAX pylons the color red. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research report ... will reach a value of USD 55.8 billion by 2025. The projection ... United States and a more open approach towards cannabis products ... Florida , North Dakota , ...
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
Breaking Medicine Technology: